Is there a generic version of Ivosidenib?

Ivosidenib (Ivosidenib) is a new type of targeted therapy drug that belongs to the IDH1 inhibitor category. The drug is mainly used to treat patients with acute myeloid leukemia (AML), especially those expressing IDH1 gene mutations.

There are generic drugs of ivonib available on the market abroad, mainly in Laos. Avosidenib is already on the market in China, but it has not yet been included in medical insurance. The price of Avosidenib on the domestic market is very high, reaching tens of thousands of yuan. For specific prices, please consult the local hospital pharmacy. The price of the American original drug of Ivonib abroad is as high as hundreds of thousands. Currently, there are generic drugs of Ivonib on the market, mainly Laos generic drugs, which cost about 10,000 yuan, which is much cheaper in comparison, and the ingredients of the original drug and the generic drug are basically the same.

AMLis a blood system disease caused by abnormal proliferation of leukemia cells in the bone marrow, and the IDH1 gene mutation is a specific genetic abnormality that is common in AML patients. This gene mutation leads to abnormal activation of the IDH1 enzyme, which participates in cell metabolism, thereby promoting the uncontrolled growth of leukemia cells.

The mechanism of action of ivonib is to specifically inhibit the abnormal activity ofIDH1 enzyme, thereby regulating the metabolic process of leukemia cells. Through this targeted treatment strategy, ivonib is expected to slow or stop the growth and proliferation of leukemia cells, providing an innovative treatment option.

Patients usually need to be tested for IDH1 gene mutations before using ivonib to ensure that their genotype meets the indications of the drug. During treatment, doctors will design a personalized medication plan based on the patient's specific conditions and conduct regular monitoring to evaluate efficacy and safety.